9.1 · Introduction to Clinical Research Ethics
Ethical conduct protects participant rights, safety, and well‑being, sustains the integrity of research, and fosters public trust.
The core principles are Respect for Persons (autonomy and informed consent), Beneficence (maximize benefit, minimize harm), and Justice (equitable selection and fair distribution of burdens/benefits).
Respect for Persons
Clear, voluntary informed consent, right to withdraw, accommodate language and comprehension needs.
Autonomy
Consent Elements
Transparency
Beneficence
Rigorous risk–benefit assessment, safety monitoring, prompt AE reporting, and protocol amendments when needed.
Risk Minimization
DSMB/Monitoring
Justice
Equitable recruitment; avoid over‑use of vulnerable groups and ensure generalizable findings.
Fair Access
No Exploitation
Key Frameworks & Guidelines
- Declaration of Helsinki — ethics principles for human research.
- Belmont Report — Respect, Beneficence, Justice.
- ICH‑GCP — harmonized good clinical practice standard.
Use the Assistant (right panel) to check consent completeness and ethics readiness.
Example
In an oncology trial, ethical conduct ensures fair treatment, minimized risk, and trustworthy data for regulatory evaluation and clinical use.
See more examples
- Detailed consent in a diabetes trial outlining purpose, procedures, risks/benefits, alternatives, and withdrawal rights.
- Risk–benefit analysis for an antiviral to ensure potential benefit justifies risk.
- Diverse recruitment for a hypertension study to support equity and generalizability.
Quick Check · Micro‑Quiz
Respect for Persons requires voluntary, informed consent with sufficient information to decide.
Beneficence means equal numbers of participants in each arm regardless of risk.
Justice allows oversampling a convenient vulnerable group to speed enrollment.
9.2 · Ethical Issues in Clinical Research
Common issues involve informed consent quality, privacy & confidentiality, risk–benefit balance, appropriate handling of vulnerable populations, conflicts of interest, and misconduct prevention.
Informed Consent Pitfalls
- Language or literacy barriers
- Therapeutic misconception
- Undue influence or time pressure
Use the Readability & Elements checker (right panel).
Privacy & Confidentiality
- De‑identification/anonymization where possible
- Encryption, role‑based access, audit trails
- Timely breach reporting
Vulnerable Populations
Children, pregnant individuals, those with impaired consent capacity — require safeguards (assent, LAR consent, risk limits, added monitoring).
Conflicts & Misconduct
Disclose financial ties; independent analysis; zero tolerance for fabrication/falsification/plagiarism; enable anonymous reporting and audits.
Quick Check · Micro‑Quiz
An AE privacy breach requires prompt reporting and remediation per policy.
Consent forms need only list benefits; risks can be discussed verbally later.
Vulnerable groups can be recruited mainly for convenience if sample size is small.
9.3 · Regulatory Compliance in Clinical Research
Compliance aligns ethical conduct with law and guidance. Key bodies include FDA (U.S.), EMA (EU), and ICH (global GCP). Core topics: protocol quality, IRB/EC approval, informed consent, monitoring & reporting, audits/inspections, and CAPA.
FDA (U.S.)
- 21 CFR Part 50 — Protection of Human Subjects
- 21 CFR Part 56 — Institutional Review Boards
- 21 CFR Part 312 — IND
EMA (EU)
- Clinical Trials Regulation (EU) No 536/2014
- GCP Directive (2005/28/EC)
ICH
- ICH E6(R2) — Good Clinical Practice
- ICH E8 — General Considerations
Quick Check · Micro‑Quiz
IRB/EC approval and valid informed consent are required before enrollment.
INDs are optional for interventional drug trials conducted in the U.S.
Monitoring safety is only necessary after marketing authorization.